ABIVAX Société Anonyme Future Growth
Future criteria checks 2/6
ABIVAX Société Anonyme is forecast to grow earnings and revenue by 2.4% and 66.1% per annum respectively. EPS is expected to decline by 4% per annum. Return on equity is forecast to be -236.6% in 3 years.
Key information
2.4%
Earnings growth rate
-4.0%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 66.1% |
| Future return on equity | -236.6% |
| Analyst coverage | Good |
| Last updated | 14 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7 | -216 | -201 | -201 | 7 |
| 12/31/2025 | 6 | -194 | -182 | -181 | 7 |
| 12/31/2024 | 8 | -166 | -123 | -123 | 7 |
| 6/30/2024 | 9 | -177 | -155 | -155 | N/A |
| 3/31/2024 | 7 | -163 | -126 | -126 | N/A |
| 12/31/2023 | 4 | -148 | -97 | -97 | N/A |
| 9/30/2023 | 4 | -120 | -77 | -77 | N/A |
| 6/30/2023 | 4 | -92 | -57 | -57 | N/A |
| 3/31/2023 | 4 | -76 | -56 | -55 | N/A |
| 12/31/2022 | 4 | -61 | -54 | -54 | N/A |
| 9/30/2022 | 8 | -54 | N/A | N/A | N/A |
| 6/30/2022 | 2 | -47 | -46 | -46 | N/A |
| 3/31/2022 | 1 | -45 | -46 | -46 | N/A |
| 12/31/2021 | 4 | -42 | -45 | -45 | N/A |
| 9/30/2021 | 0 | -41 | N/A | N/A | N/A |
| 6/30/2021 | 0 | -39 | -46 | -45 | N/A |
| 3/31/2021 | 0 | -38 | -38 | -38 | N/A |
| 12/31/2020 | 0 | -38 | -31 | -30 | N/A |
| 9/30/2020 | 0 | -35 | N/A | N/A | N/A |
| 6/30/2020 | 0 | -32 | -25 | -24 | N/A |
| 3/31/2020 | 0 | -31 | -27 | -26 | N/A |
| 12/31/2019 | 0 | -31 | -28 | -27 | N/A |
| 9/30/2019 | 0 | -27 | -23 | -22 | N/A |
| 6/30/2019 | 0 | -23 | -18 | -17 | N/A |
| 3/31/2019 | 1 | -19 | -17 | -16 | N/A |
| 12/31/2018 | 1 | -16 | -15 | -15 | N/A |
| 9/30/2018 | 1 | -14 | -14 | -13 | N/A |
| 6/30/2018 | 1 | -13 | -12 | -11 | N/A |
| 3/31/2018 | 1 | -12 | N/A | -10 | N/A |
| 12/31/2017 | 0 | -11 | N/A | -8 | N/A |
| 9/30/2017 | 0 | -11 | N/A | N/A | N/A |
| 6/30/2017 | 0 | -12 | N/A | -11 | N/A |
| 3/31/2017 | 0 | -13 | N/A | -14 | N/A |
| 12/31/2016 | 0 | -14 | N/A | -16 | N/A |
| 9/30/2016 | 0 | -16 | N/A | N/A | N/A |
| 6/30/2016 | 0 | -17 | N/A | -24 | N/A |
| 3/31/2016 | 0 | -17 | N/A | -19 | N/A |
| 12/31/2015 | 0 | -16 | N/A | -15 | N/A |
| 9/30/2015 | 0 | -14 | N/A | N/A | N/A |
| 6/30/2015 | 0 | -12 | N/A | N/A | N/A |
| 3/31/2015 | 0 | -8 | N/A | N/A | N/A |
| 12/31/2014 | 0 | -5 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABVX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABVX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABVX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABVX's revenue (66.1% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ABVX's revenue (66.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABVX is forecast to be unprofitable in 3 years.